P/E - Epizyme Inc (F:EPE) - Alpha Spread
E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33% Market Closed
Market Cap: 92.2B EUR
Have any thoughts about
Epizyme Inc?
Write Note

P/E
Price to Earnings

-504
Current
-483.3
Median
23.9
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-504
=
Market Cap
94.1B EUR
/
Net Income
-207.7m USD
All Countries
Close
Earnings Growth
US
E
Epizyme Inc
F:EPE
Average P/E: 57.4
Negative Multiple: -504
N/A
US
Abbvie Inc
NYSE:ABBV
64.3
406%
US
Amgen Inc
NASDAQ:AMGN
57.4
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.4
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.1
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
AU
CSL Ltd
ASX:CSL
36.5
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 219.7 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -479.1 N/A
NL
argenx SE
NASDAQ:ARGX
Negative Multiple: -114.2 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-345.4
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A

See Also

Discover More